Meeting
2023 ASCO Annual Meeting
Validation of a guidelines-based brief patient-administered digital tool to assess the need for germline genetic testing.
Authors
Callan Russell
Northside Hospital, Atlanta, GA
Callan Russell , Ashley Daley , Durand Van Arnem , Andi Hila , Kiley Johnson , Jill Davies , Colleen Caleshu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10605)
DOI
10.1200/JCO.2023.41.16_suppl.10605
Abstract #
10605
Poster Bd #
238
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Connecting Black families in Houston, Texas, to hereditary cancer genetic counseling, genetic testing, and cascade testing by using a simple cancer genetic risk assessment and telegenetics.
First Author: Darya Aleksandrovna Kizub
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Risks and implications of multiple actionable pathogenic germline variants discovered by panel-based cancer predisposition testing.
First Author: Michael J. Hall
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Pathogenic germline mutations prevalence in Saudi patients with pancreatic ductal adenocarcinoma.
First Author: Mohammed Ahmed Algarni
Poster
2019 ASCO Annual Meeting
Adequacy of self-reported family history in electronic health record for genetic risk assessment for Lynch syndrome.
First Author: Mala Pande